View Clinical Trial (Medical Research Study)

A Randomized, Controlled Trial of Fluvastatin Added to Pegylated Interferon and Ribavirin (PI+R) Versus PI+R Alone for Treatment of Chronic Hepatitis C Not Previously Treated - NCT00487318-73104(Clinical Trial 172590)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  OKlahoma City
State:  
OK
Zip Code: 73104
Conditions: Chronic Hepatitis C
Purpose: Hypothesis: addition of fluvastatin will increase the cure rate of standard anti-HCV therapy. Summary: This trial is limited to veterans in Oklahoma who qualify for care with the Veterans Administration. It is a randomized control format including genotypes 1 and 3. There will also be pilot arms for HCV carriers who present for screening already on a statin, who will be allowed to stay on their current statin or switched to another statin. In all ways, standard therapy as noted on pegylated interferon and ribavirin will be given per FDA package insert.
Study summary:
Criteria: Inclusion Criteria: - Not previously treated. - Off alcohol and marijuana for 6 months - HCV RNA positive Exclusion Criteria: - HIV positive - Advanced liver disease - Advanced cardiopulmonary disease - Chronic renal failure
Study is available at: VA Hospital
OKlahoma City, OK 73104
United States

Primary Contact:
Joe Cardello
Email: jcardello1@cox.net
Phone: 405-270-0501
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 22, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.